Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Reasonable Options for Initial Treatment of Parkinson Disease

21.07.2004


The drugs levodopa and pramipexole both appear to be reasonable options as initial therapy for Parkinson disease, but they are associated with different efficacy and adverse effects, according to an article in the July issue of The Archives of Neurology, one of the JAMA/Archives journals.



Parkinson disease is a progressive neurologic disease. It is believed to be related to low levels of the important neurotransmitter (messenger) dopamine in certain parts of the brain. When the drug levodopa is taken orally, it crosses through the “blood-brain barrier” and is converted to dopamine. Another drug, carbidopa, is added to levodopa to prevent the breakdown of levodopa before it crosses into the brain. Pramipexole is one of several drugs that mimic the role of dopamine in the brain, causing the neurons to react as they would to dopamine.

The Parkinson Study Group conducted a multicenter, parallel-group, double-blind, randomized controlled trial to compare initial treatment with pramipexole vs. levodopa in early Parkinson disease, followed by levodopa supplementation, with respect to the development of motor complications, other adverse events, and functional and quality of life outcomes. Robert G. Holloway, M.D., M.P.H., of the University of Rochester, Rochester, N.Y., and colleagues reported the results for the Parkinson Study Group.


Patients with early Parkinson disease who required dopaminergic therapy (relating to nerve cells or fibers that employ dopamine as their neurotransmitter) to treat emerging disability enrolled in the study between October 1996 and August 1997. Among 301 patients, 151 were randomly assigned to receive 0.5 milligrams of pramipexole three times per day with levodopa placebo. The other 150 patients received 25/100 milligrams of carbidopa/levodopa three times per day with pramipexole placebo. Dosage was escalated during the first ten weeks for patients with ongoing disability. After that, the investigators were permitted to add open-label levodopa or other anti-Parkinsonian medications to treat ongoing or emerging disability. The patients were observed until August 2001.

“Initial pramipexole treatment resulted in a significant reduction in the risk of developing dyskinesias [uncontrollable body movements; 24.5 percent vs. 54 percent with initial treatment with levodopa] and wearing off [47 percent vs. 62.7 percent with initial treatment with levodopa],” the authors write.

Initial levodopa treatment resulted in a significant reduction in the risk of “freezing” of motor function [25.3 percent vs. 37.1 percent with initial treatment with pramipexole], the researchers report.

Initial treatment with levodopa also resulted in lower incidences of somnolence (sleepiness; 36 percent vs. 21 percent), and edema (excess fluid in the tissues; 42 percent vs. 15 percent) and provided for better symptomatic control, as measured by the Unified Parkinson Disease Rating Scale.

By 48 months, the occurrence of disabling dyskinesias was uncommon and did not significantly differ between the two groups. Both options resulted in similar quality of life.

“Pramipexole and levodopa are associated with different efficacy and adverse-effect profiles. These differences are insufficient to identify a preferred strategy; hence, both pramipexole and levodopa appear to be reasonable options as initial dopaminergic therapy in Parkinson disease,” the authors conclude.

“Long-term follow-up is needed to determine if either treatment strategy is superior to the other in terms of patient impairment, disability, or quality of life,” they write.

| newswise
Further information:
http://www.ama-assn.org
http://archneurol.com

More articles from Health and Medicine:

nachricht World first: Massive thrombosis removed during early pregnancy
20.07.2017 | Universitätsspital Bern

nachricht Therapy of preterm birth in sight?
19.07.2017 | Universitätsspital Bern

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Manipulating Electron Spins Without Loss of Information

Physicists have developed a new technique that uses electrical voltages to control the electron spin on a chip. The newly-developed method provides protection from spin decay, meaning that the contained information can be maintained and transmitted over comparatively large distances, as has been demonstrated by a team from the University of Basel’s Department of Physics and the Swiss Nanoscience Institute. The results have been published in Physical Review X.

For several years, researchers have been trying to use the spin of an electron to store and transmit information. The spin of each electron is always coupled...

Im Focus: The proton precisely weighted

What is the mass of a proton? Scientists from Germany and Japan successfully did an important step towards the most exact knowledge of this fundamental constant. By means of precision measurements on a single proton, they could improve the precision by a factor of three and also correct the existing value.

To determine the mass of a single proton still more accurate – a group of physicists led by Klaus Blaum and Sven Sturm of the Max Planck Institute for Nuclear...

Im Focus: On the way to a biological alternative

A bacterial enzyme enables reactions that open up alternatives to key industrial chemical processes

The research team of Prof. Dr. Oliver Einsle at the University of Freiburg's Institute of Biochemistry has long been exploring the functioning of nitrogenase....

Im Focus: The 1 trillion tonne iceberg

Larsen C Ice Shelf rift finally breaks through

A one trillion tonne iceberg - one of the biggest ever recorded -- has calved away from the Larsen C Ice Shelf in Antarctica, after a rift in the ice,...

Im Focus: Laser-cooled ions contribute to better understanding of friction

Physics supports biology: Researchers from PTB have developed a model system to investigate friction phenomena with atomic precision

Friction: what you want from car brakes, otherwise rather a nuisance. In any case, it is useful to know as precisely as possible how friction phenomena arise –...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Closing the Sustainability Circle: Protection of Food with Biobased Materials

21.07.2017 | Event News

»We are bringing Additive Manufacturing to SMEs«

19.07.2017 | Event News

The technology with a feel for feelings

12.07.2017 | Event News

 
Latest News

NASA looks to solar eclipse to help understand Earth's energy system

21.07.2017 | Earth Sciences

Stanford researchers develop a new type of soft, growing robot

21.07.2017 | Power and Electrical Engineering

Vortex photons from electrons in circular motion

21.07.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>